Genetic Signatures Ltd. · ASX:GSS
Genetic Signatures — H1 2022 Earnings Presentation
11 slides from Genetic Signatures's earnings presentation, Feb 18, 2022
Slide 1: Company Presentation – 1H FY22
For personal use only Company Presentation – 1H FY22 FEBRUARY 2022
Slide 2: Disclaimer
Investor DOCUMENT Presentation TITLE Disclaimer SEPTEMBER February 2021 2022 This presentation has been prepared by Genetic Signatures Limited ACN 095 913 205 (the Company or GSS) and approved by the Board of Directors for release. It comprises written For personal use only materials/slides for a ve
Slide 3: Company Summary
Company Summary Investor DOCUMENT Presentation SEPTEMBER TITLE FEBRUARY 2021 2022 Established ASX listed developer and manufacturer of molecular For personal use only (PCR) based test kits for infectious diseases Novel 3base® technology – changes DNA sequence, detects the most common mutations, rapi
Slide 4: Trusted & Proven Technology
Trusted & Proven Technology Investor DOCUMENT Presentation SEPTEMBER TITLE FEBRUARY 2021 2022 A ‘Syndromic Screening’ approach allows users to test a broad range of clinically relevant pathogens based For personal use only on patient symptoms, helping clinicians make an accurate diagnosis EasyScreen
Slide 5: Financial Summary – Sales
Financial Summary – Sales Investor DOCUMENT Presentation SEPTEMBER TITLE FEBRUARY 2021 2022 Revenue from sales (A$m) Continued Strong Revenue Growth For personal use only 28.3 2Q FY22 $9.4m, up 16% on pcp Strong local demand for SARS-CoV-2 tests 5.4 continue due to ongoing outbreaks 21.8 4.2 Interna
Slide 6: Financial Summary – 1H FY22 Profit & Loss
Financial Summary – 1H FY22 Profit & Loss Investor DOCUMENT Presentation SEPTEMBER TITLE FEBRUARY 2021 2022 Profitable while growing business For personal use only A'000s 1H FY22 1H FY21 Sales revenue 21,838 18,693 17% increase in 1H sales over pcp Cost of materials & freight (6,890) (6,086) Gross p
Slide 7: EasyScreen Detection Kit Range
EasyScreenTM Detection Kit Range Investor DOCUMENT Presentation TITLE SEPTEMBER FEBRUARY 2021 2022 Registrations Current In process For personal use only Enteric * Detects 20+ gastroenteritis pathogens including Salmonella, Giardia and Norovirus Respiratory US EUA Detects 14 common respiratory infec
Slide 8: Enteric Protozoan Product
Enteric Protozoan Product Investor DOCUMENT Presentation SEPTEMBER TITLE FEBRUARY 2021 2022 Market Dynamics For personal use only Est. 5.5m Enteric Protozoan tests pa in the US Initial focus on largest 30 “high throughput” centralised labs Smaller decentralised labs more accessible with development
Slide 9: Next Steps – Beyond COVID
For personal use only Next Steps – Beyond COVID Investor DOCUMENT Presentation SEPTEMBER TITLE FEBRUARY 2021 2022 Leverage COVID-19 – new customers, new tests Continue building interest in EasyScreenTM kits in US & EU markets using expanded sales teams and SARS-CoV-2 experience as leverage SARS-CoV-
Slide 10: Reasons to Invest
For personal use only Reasons to Invest Investor DOCUMENT Presentation SEPTEMBER TITLE FEBRUARY 2021 2022 Attractive investment proposition • Business model with Continued product expansion favourable unit economics • 5 product groups in • Increasing international development recognition via EasyScr
Slide 11: Contact us
For personal use only Contact us Dr John Melki Genetic Signatures Chief Executive Officer P: +61 (0)2 9870 7580 E: john.melki@geneticsignatures.com Visit us www.geneticsignatures.com Follow us 11